Millendo Therapeutics has started a phase 1 clinical trial of its selective neurokinin 3 receptor (NK3R) antagonist MLE-301, which is being developed for the treatment of menopausal women with vasomotor symptoms (VMS). VMS is known commonly as hot flashes and night sweats in menopausal women. The Michigan-based biopharma company has dosed the first subject in […]
Millendo Therapeutics has finalized its merger with OvaScience, a Massachusetts-based biotech firm specializing in female infertility treatments. The transaction, initially announced in August 2018, concludes with Millendo receiving a total of $85.4 million. This sum comprises $35.9 million in cash from OvaScience and an additional $49.5 million from a related financing effort. The merger’s completion […]
